who's taking entitlement, page-25

Under Rebecca's leadership, shareholders have watched 83% of our investment disappear.

Is it her leadership style or is it the influence of other Board members who are pulling the strings? Either way, wouldn't you think you'd be taking a look at the way you operate and do some self-reflection and ask yourself is there anything we can do differently to improve the Company?

I agree with @maxswell that the tech looks promising, but if you do not have the right people steering the ship, it will fall off the face of the earth!

This is a message I sent to Rebecca on LInkedin. Since then, they're finally providing me with the register. And Rebecca has blocked me!! What does that tell you about what the Company thinks of its shareholders? Unless there are changes made to the structure of the Board, I can't see things improving.

I am writing to you again as a concerned shareholder of Chimeric Therapeutics. Over the course of my 20 years in investing, I have encountered various approaches to corporate governance, but I must express my deep disappointment with the way Chimeric has been conducting itself. Transparency, regulatory compliance, and shareholder engagement are fundamental pillars of a successful public company, yet recent actions by Chimeric indicate a significant failure in these areas.

Key Concerns:

Failure to Provide a Complete Share Register: As you are aware, I made a formal request for the share register, yet I was only provided with a partial version, omitting key states. This appears to be a clear breach of the Corporations Act and raises serious concerns about the Company’s commitment to transparency and compliance. ASIC’s lack of enforcement in such matters does not absolve the Company of its legal responsibilities.

Investor Relations and Capital Raising Challenges: Given Chimeric’s approach to governance and lack of transparency, I struggle to see how the Company expects to secure future capital. Shareholders are the backbone of any listed company, yet they are treated with disregard—until capital needs arise. This approach is unsustainable and will severely impact the Company's ability to raise funds and attract serious institutional investment.

Lack of Leadership Guidance: As this is your first role as CEO, it is critical that you are surrounded by experienced advisors who prioritise governance, compliance, and long-term value creation. From my perspective, it appears that you are receiving poor advice, which is leading to missteps in corporate strategy and investor communication.

Suggested Improvements:

Strengthen Corporate Governance: Adopting best-practice governance standards, ensuring full compliance with regulatory requirements, and providing clear, transparent disclosures to shareholders.

Enhance Shareholder Communication: Establishing an open and constructive dialogue with investors through regular engagement, prompt responses to concerns, and a commitment to transparency.

Rebuild Investor Trust: Implementing measures to restore credibility, including ensuring all market-sensitive announcements are appropriately disclosed via the ASX rather than selectively shared through LinkedIn or other channels.

Independent Oversight: Bringing in experienced external advisors or board members with a proven track record in governance and biotech leadership to guide the Company towards sustainable success.

I strongly believe that Chimeric Therapeutics has the potential to succeed, but the current trajectory is undermining investor confidence and the Company’s future. I urge you to take immediate steps to address these concerns before irreparable damage is done. I am more than willing to discuss these issues further if you wish to engage in a constructive dialogue.

I look forward to your response.

Kind Regards,